What are the major opportunities in the Nucleic Acid And Gene Therapies In Neuromuscular Disorders market? What are the strategies for the Nucleic Acid And Gene Therapies In Neuromuscular Disorders market?

For detailed insights on the major opportunities and strategies in the Nucleic Acid And Gene Therapies In Neuromuscular Disorders market, Read More

How does the Nucleic Acid And Gene Therapies In Neuromuscular Disorders market relate to the overall economy and other similar markets?

For detailed insights on the key dynamics influencing the Nucleic Acid And Gene Therapies In Neuromuscular Disorders market growth and SWOT analysis of the Nucleic Acid And Gene Therapies In Neuromuscular Disorders industry, Read More

Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Report 2025

Item added to cart!

Published : December 2025

Pages : 175

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00

Purchase This Report Download Sample PDF

Purchase This Report

Nucleic Acid And Gene Therapies In Neuromuscular Disorders Global Market Report 2025

Name: Nucleic Acid And Gene Therapies In Neuromuscular Disorders Global Market Report 2025
Brand: The Business Research Company
Price: 4490.00 USD
Availability: InStock

By Disorder (Motor Neuron Diseases, Neuropathies, Neuromuscular Junction Disorders, Myopathies Including Muscular Dystrophies), By Therapy (Adeno-Associated Viruses Gene Therapy, Postnatal Gene Therapy, Spinal Muscular Atrophy), By Application (Hospitals, Specialty Clinics, Ambulatory Surgery Centers) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview

• Nucleic Acid And Gene Therapies In Neuromuscular Disorders market size has reached to $6.84 billion in 2024

• Expected to grow to $10.78 billion in 2029 at a compound annual growth rate (CAGR) of 9.5%

• Growth Driver: Rising Prevalence Of Genetic Disorders Fuels Growth In The Market

• Market Trend: Advancements In Gene Therapy For Neuromuscular Disorders

• North America was the largest region in 2024.

What Is Covered Under Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market?

Nucleic acid and gene therapies in neuromuscular disorders refer to innovative treatments that aim to correct or compensate for the genetic mutations underlying these diseases. Neuromuscular disorders (NMDs) are conditions that affect the muscles and nerves, often due to inherited genetic mutations. These therapies involve the use of nucleic acids or genetic material to repair, replace, or modulate gene expression, thereby addressing the root cause of the disorder.

The main disorders in nucleic acid and gene therapies in neuromuscular disorders are motor neuron diseases, neuropathies, neuromuscular junction disorders, and myopathies including muscular dystrophies. Motor neuron diseases refer to a group of progressive neurological disorders that affect motor neurons, leading to muscle weakness, atrophy, and loss of voluntary movement control. The therapies include adeno-associated viruses gene therapy, postnatal gene therapy, and spinal muscular atrophy. The various applications include hospitals, specialty clinics, and ambulatory surgery centers.

Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Size and growth rate 2025 to 2029: Graph

What Is The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Size 2025 And Growth Rate?

What Is The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Growth Forecast?

The nucleic acid and gene therapies in neuromuscular disorders market size is expected to see strong growth in the next few years. It will grow to $10.78 billion in 2029 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to increasing prevalence of genetic disorders, increasing investments in research and development, growing demand for precision medicine, rising approval of gene therapy products, and increasing prevalence of chronic disorders. Major trends in the forecast period include advances in patient care, high performance chromatography, innovative solutions for conditions, advancements in gene editing technologies, and availability of nucleic acid extraction technology.

The forecast of 9.5% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may disrupt U.S. medical innovation by increasing costs for Adeno-associated virus vector-based therapies and Clustered regularly interspaced short palindromic repeats -Cas9 components imported from Switzerland and South Korea, potentially raising specialty pharmacy costs and postponing rare disease treatments. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Book your 30 minutes free consultation with our research experts

What’s The Trade War Impact On Healthcare Services Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

How Is The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Segmented?

1) By Disorder: Motor Neuron Diseases, Neuropathies, Neuromuscular Junction Disorders, Myopathies Including Muscular Dystrophies

2) By Therapy: Adeno-Associated Viruses Gene Therapy, Postnatal Gene Therapy, Spinal Muscular Atrophy

3) By Application: Hospitals, Specialty Clinics, Ambulatory Surgery Centers

Subsegments:

1) By Motor Neuron Diseases: Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA), Primary Lateral Sclerosis (PLS)

2) By Neuropathies: Charcot-Marie-Tooth Disease (CMT), Hereditary Sensory and Autonomic Neuropathy (HSAN), Peripheral Neuropathies

3) By Neuromuscular Junction Disorders: Myasthenia Gravis, Lambert-Eaton Myasthenic Syndrome (LEMS)

4) By Myopathies Including Muscular Dystrophies: Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (BMD), Limb-Girdle Muscular Dystrophy (LGMD), Facioscapulohumeral Muscular Dystrophy (FSHD)

What Is Driving The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market? Rising Prevalence Of Genetic Disorders Fuels Growth In The Market

The increasing prevalence of genetic disorders is expected to propel the growth of the nucleic acid and gene therapies in neuromuscular disorders market going forward. Genetic disorders are diseases caused by abnormalities in an individual's DNA, either inherited or resulting from mutations. The increase in genetic disorders is due to factors such as genetic mutations, environmental influences, lifestyle changes, and improved diagnostic capabilities. Nucleic acid and gene therapies help genetic disorders by correcting or replacing defective genes in neuromuscular conditions to restore normal function. For instance, in May 2024, according to Cure SMA, a US-based non-profit organization, In the United States, approximately 9,000 to 9,500 individuals are currently living with Spinal Muscular Atrophy (SMA). Among the total population, 37% have Type 2 SMA. The condition has an estimated incidence rate of 1 in 15,000 births. Therefore, the increasing prevalence of genetic disorders is driving the growth of the nucleic acid and gene therapies in neuromuscular disorders industry.

Who Are The Major Players In The Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market?

Major companies operating in the nucleic acid and gene therapies in neuromuscular disorders market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Sanofi S.A, Novartis AG, Eli Lilly and Company, Astellas Pharma Inc, Biogen Inc, Vertex Pharmaceuticals Inc, BioMarin Pharmaceuticals Inc, Nippon Shinyaku Co Ltd, Sarepta Therapeutics Inc, Ionis Pharmaceuticals, Inc., Ultragenyx Pharmaceutical Inc, Amicus Therapeutics Inc, Arrowhead Pharmaceuticals Inc, Regenxbio Inc, UniQure N.V., Généthon S.A, Axovant Gene Therapies Inc.

What Are The Key Trends Of The Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market? Advancements In Gene Therapy For Neuromuscular Disorders

Major companies are operating in the nucleic acid and gene therapies in neuromuscular disorders market, focusing on developing innovative therapies such as gene therapy to address the root causes of genetic neuromuscular conditions through targeted gene correction or replacement. Gene therapy refers to the treatment of diseases by introducing, altering, or repairing genetic material within a patient's cells to correct or replace defective genes. For instance, in June 2023, Sarepta Therapeutics Inc., a US-based biotechnology company, received approval from the U.S. Food and Drug Administration for Elevidys, the first gene therapy for Duchenne Muscular Dystrophy, specifically for ambulatory pediatric patients aged 4 to 5 years. The therapy is administered as a single intravenous infusion, simplifying the treatment process compared to other therapies that may require ongoing infusions. ELEVIDYS delivers a gene that codes for a shortened form of dystrophin known as micro-dystrophin, which is essential for muscle function. This innovative approach addresses the underlying genetic defect by enabling muscle cells to produce a functional version of the dystrophin protein, thereby potentially halting or reversing disease progression.

Need data on a specific region in this market?

Request Regional Data

What Are Latest Mergers And Acquisitions In The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market? Novartis Acquires Kate Therapeutics To Boost Gene Therapy Pipeline For Inherited Neuromuscular Diseases

In November 2024, Novartis AG, a Switzerland-based pharmaceutical company, acquired Kate Therapeutics Inc. for $1.1 billion. With this acquisition, Novartis aims to enhance its gene therapy capabilities for inherited neuromuscular diseases by integrating AAV-based gene therapy platform DELIVER and preclinical candidates for Duchenne muscular dystrophy, facioscapulohumeral dystrophy and myotonic dystrophy type 1 into its portfolio. Kate Therapeutics Inc. is a US-based biotechnology company focused on developing adeno-associated virus (AAV)-based gene therapies for genetically defined muscle and heart diseases.

What Is The Regional Outlook For The Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market?

North America was the largest region in the nucleic acid and gene therapies in neuromuscular disorders market in 2024. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market?

The nucleic acid and gene therapies in neuromuscular disorders market consist of revenue earned by entities by providing services such as genetic diagnostics, personalized therapeutics, and gene delivery. The market value includes the value of related goods sold by the service provider or included within the service offering. The nucleic acid and gene therapies in neuromuscular disorders market also include sales of oligonucleotides, gene therapy vectors, and diagnostic kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Nucleic Acid And Gene Therapies In Neuromuscular Disorders Industry?

The nucleic acid and gene therapies in neuromuscular disorders market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the nucleic acid and gene therapies in neuromuscular disorders industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author : Abdul Wasay

Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2025	$7.5 billion
Revenue Forecast In 2034	$10.78 billion
Growth Rate	CAGR of 9.5% from 2025 to 2034
Base Year For Estimation	2024
Actual Estimates/Historical Data	2019-2024
Forecast Period	2025 - 2029 - 2034
Market Representation	Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered	The nucleic acid and gene therapies in neuromuscular disorders market covered in this report is segmented – 1) By Disorder: Motor Neuron Diseases, Neuropathies, Neuromuscular Junction Disorders, Myopathies Including Muscular Dystrophies 2) By Therapy: Adeno-Associated Viruses Gene Therapy, Postnatal Gene Therapy, Spinal Muscular Atrophy 3) By Application: Hospitals, Specialty Clinics, Ambulatory Surgery Centers Subsegments: 1) By Motor Neuron Diseases: Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA), Primary Lateral Sclerosis (PLS) 2) By Neuropathies: Charcot-Marie-Tooth Disease (CMT), Hereditary Sensory and Autonomic Neuropathy (HSAN), Peripheral Neuropathies 3) By Neuromuscular Junction Disorders: Myasthenia Gravis, Lambert-Eaton Myasthenic Syndrome (LEMS) 4) By Myopathies Including Muscular Dystrophies: Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (BMD), Limb-Girdle Muscular Dystrophy (LGMD), Facioscapulohumeral Muscular Dystrophy (FSHD)
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled	Pfizer Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Sanofi S.A, Novartis AG, Eli Lilly and Company, Astellas Pharma Inc, Biogen Inc, Vertex Pharmaceuticals Inc, BioMarin Pharmaceuticals Inc, Nippon Shinyaku Co Ltd, Sarepta Therapeutics Inc, Ionis Pharmaceuticals, Inc., Ultragenyx Pharmaceutical Inc, Amicus Therapeutics Inc, Arrowhead Pharmaceuticals Inc, Regenxbio Inc, UniQure N.V., Généthon S.A, Axovant Gene Therapies Inc.
Customization Scope	Request for Sample
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

2. Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Characteristics

3. Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Trends And Strategies

4. Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Growth Analysis And Strategic Analysis Framework

5.1. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Growth Rate Analysis

5.4. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Total Addressable Market (TAM)

6. Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Segmentation

6.1. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Motor Neuron Diseases

Neuropathies

Neuromuscular Junction Disorders

Myopathies Including Muscular Dystrophies

6.2. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Adeno-Associated Viruses Gene Therapy

Postnatal Gene Therapy

Spinal Muscular Atrophy

6.3. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospitals

Specialty Clinics

Ambulatory Surgery Centers

6.4. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Sub-Segmentation Of Motor Neuron Diseases, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Amyotrophic Lateral Sclerosis (ALS)

Spinal Muscular Atrophy (SMA)

Primary Lateral Sclerosis (PLS)

6.5. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Sub-Segmentation Of Neuropathies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Charcot-Marie-Tooth Disease (CMT)

Hereditary Sensory and Autonomic Neuropathy (HSAN)

Peripheral Neuropathies

6.6. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Sub-Segmentation Of Neuromuscular Junction Disorders, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Myasthenia Gravis

Lambert-Eaton Myasthenic Syndrome (LEMS)

7. Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Regional And Country Analysis

7.1. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

8.1. Asia-Pacific Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

9.1. China Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview

9.2. China Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

10.1. India Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

11.1. Japan Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview

11.2. Japan Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

12.1. Australia Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

13.1. Indonesia Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

14.1. South Korea Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview

14.2. South Korea Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

15.1. Western Europe Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview

15.2. Western Europe Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

16.1. UK Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

17.1. Germany Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

18.1. France Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

19.1. Italy Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

20.1. Spain Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

21.1. Eastern Europe Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview

21.2. Eastern Europe Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

22.1. Russia Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

23.1. North America Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview

23.2. North America Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

24.1. USA Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview

24.2. USA Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

25.1. Canada Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview

25.2. Canada Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

26.1. South America Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview

26.2. South America Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

27.1. Brazil Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

28.1. Middle East Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview

28.2. Middle East Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

29.1. Africa Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview

29.2. Africa Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Competitive Landscape And Company Profiles

30.1. Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Competitive Landscape

30.2. Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Company Profiles

30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Sanofi S.A Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Other Major And Innovative Companies

31.1. Eli Lilly and Company

31.2. Astellas Pharma Inc

31.3. Biogen Inc

31.4. Vertex Pharmaceuticals Inc

31.5. BioMarin Pharmaceuticals Inc

31.6. Nippon Shinyaku Co Ltd

31.7. Sarepta Therapeutics Inc

31.8. Ionis Pharmaceuticals, Inc.

31.9. Ultragenyx Pharmaceutical Inc

31.10. Amicus Therapeutics Inc

31.11. Arrowhead Pharmaceuticals Inc

31.12. Regenxbio Inc

31.13. UniQure N.V.

31.14. Généthon S.A

31.15. Axovant Gene Therapies, Inc

32. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

34. Recent Developments In The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

35. Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market High Potential Countries, Segments and Strategies

35.1 Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market In 2029 - Countries Offering Most New Opportunities

35.2 Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market In 2029 - Segments Offering Most New Opportunities

35.3 Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Historic Market Growth, 2019-2024, $ Billion

Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Table 3: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 4: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 5: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 6: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Sub-Segmentation Of Motor Neuron Diseases, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 7: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Sub-Segmentation Of Neuropathies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 8: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Sub-Segmentation Of Neuromuscular Junction Disorders, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 9: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 10: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 11: Asia-Pacific, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 12: Asia-Pacific, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 13: Asia-Pacific, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 14: China, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 15: China, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 16: China, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 17: India, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 18: India, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 19: India, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 20: Japan, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 21: Japan, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 22: Japan, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 23: Australia, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 24: Australia, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 25: Australia, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 26: Indonesia, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 27: Indonesia, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 28: Indonesia, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 29: South Korea, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 30: South Korea, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 31: South Korea, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 32: Western Europe, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 33: Western Europe, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 34: Western Europe, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 35: UK, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 36: UK, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 37: UK, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 38: Germany, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 39: Germany, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 40: Germany, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 41: France, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 42: France, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 43: France, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 44: Italy, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 45: Italy, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 46: Italy, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 47: Spain, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 48: Spain, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 49: Spain, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 50: Eastern Europe, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 51: Eastern Europe, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 52: Eastern Europe, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 53: Russia, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 54: Russia, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 55: Russia, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 56: North America, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 57: North America, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 58: North America, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 59: USA, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 60: USA, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 61: USA, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 62: Canada, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 63: Canada, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 64: Canada, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 65: South America, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 66: South America, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 67: South America, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 68: Brazil, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 69: Brazil, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 70: Brazil, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 71: Middle East, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 72: Middle East, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 73: Middle East, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 74: Africa, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 75: Africa, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 76: Africa, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 77: Pfizer Inc. Financial Performance

Table 78: F. Hoffmann-La Roche Ltd. Financial Performance

Table 79: Bayer AG Financial Performance

Table 80: Sanofi S.A Financial Performance

Table 81: Novartis AG Financial Performance

List Of Figures

Figure 1: Global Historic Market Growth, 2019-2024, $ Billion

Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Figure 3: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 4: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 5: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 6: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Sub-Segmentation Of Motor Neuron Diseases, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 7: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Sub-Segmentation Of Neuropathies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 8: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Sub-Segmentation Of Neuromuscular Junction Disorders, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 9: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 10: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 11: Asia-Pacific, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 12: Asia-Pacific, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 13: Asia-Pacific, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 14: China, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 15: China, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 16: China, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 17: India, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 18: India, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 19: India, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 20: Japan, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 21: Japan, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 22: Japan, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 23: Australia, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 24: Australia, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 25: Australia, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 26: Indonesia, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 27: Indonesia, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 28: Indonesia, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 29: South Korea, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 30: South Korea, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 31: South Korea, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 32: Western Europe, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 33: Western Europe, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 34: Western Europe, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 35: UK, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 36: UK, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 37: UK, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 38: Germany, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 39: Germany, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 40: Germany, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 41: France, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 42: France, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 43: France, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 44: Italy, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 45: Italy, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 46: Italy, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 47: Spain, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 48: Spain, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 49: Spain, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 50: Eastern Europe, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 51: Eastern Europe, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 52: Eastern Europe, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 53: Russia, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 54: Russia, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 55: Russia, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 56: North America, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 57: North America, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 58: North America, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 59: USA, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 60: USA, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 61: USA, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 62: Canada, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 63: Canada, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 64: Canada, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 65: South America, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 66: South America, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 67: South America, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 68: Brazil, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 69: Brazil, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 70: Brazil, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 71: Middle East, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 72: Middle East, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 73: Middle East, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 74: Africa, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 75: Africa, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 76: Africa, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 77: Pfizer Inc. Financial Performance

Figure 78: F. Hoffmann-La Roche Ltd. Financial Performance

Figure 79: Bayer AG Financial Performance

Figure 80: Sanofi S.A Financial Performance

Figure 81: Novartis AG Financial Performance

Intestinal Fistula Treatment Market Overview 2025: Competitive Shifts, Forecast Models, and Emerging Opportunities

Next-Gen Invasive Aspergillosis Therapeutics : Market Forecast, Transformation, and Long-Term Trajectories

Iron Deficiency Anemia Growth Trajectory: Key Forecasts and Strategic Insights

Lewy Body Dementia Market 2025-2034: Key Highlights, Growth Dynamics, and Emerging Trends

A strategic 2025 report providing key insights, trends and forecasts for the global live attenuated polio vaccine market between 2025–2034.

A 2025 forecast report outlining growth projections, key trends and regulatory landscape of the medicated shampoo market through 2029.

A 2025 strategic report on market size, competitive landscape and expansion strategies in the medications for heart failure market.

Explore strategic insights and forecasts in the global virtual nutrition coach app market, offering competitive benchmarking and market growth trends.

Gene Therapy Global Market Report 2025 – By Gene Therapy Type (Germline Therapy, Somatic Cell Therapy), By Vector (Viral Vector, Non-Viral Vector), By Application (Oncology, Orphan Disease, Knee Osteoarthritis, Neurologi...

Oligonucleotide Therapy Global Market Report 2025 – By Type (Antisense Oligonucleotide, Aptamer, Other Types), By Application (Infectious Diseases, Oncology, Neurodegenerative Disorders, Cardiovascular Diseases, Kidney D...

Ribose-Nucleic Acid (RNA)-Based Therapeutics Global Market Report 2025 – By Type (RNA Interference (RNAi), RNA Antisense), By Technology (Enabling Technology, Enabled Technology), By Therapeutic Area (Oncology, Genetic D...

mRNA Therapeutics Global Market Report 2025 – By Product (Vaccines, Drugs), By Application (Infectious Diseases, Oncology, Rare Genetic Diseases, Respiratory Diseases, Other Applications), By End Use (Hospitals And Clini...

Neurological Disorder Drugs Global Market Report 2025 – By Drug Class (Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Antiepileptic, Antipsychotic And Antidepressant, Other Drugs Classes), B...

Duchenne Muscular Dystrophy (DMD) Therapeutics Global Market Report 2025 – By Type (Small Molecules, Biologics), By Distribution Channel (Offline, Online), By Application (Hospitals, Clinics, Home Care) – Impact of Tarif...

Duchenne Muscular Dystrophy Global Market Report 2025 – By Therapy (Mutation Suppression, Exon Skipping Approach), By Therapeutic Class (Molecular Based Therapies, Steroid Therapy), By Route of Administration (Oral, Pare...

Frequently Asked Questions

What is the definition of the Nucleic Acid And Gene Therapies In Neuromuscular Disorders market?

How will the Nucleic Acid And Gene Therapies In Neuromuscular Disorders market drivers and restraints affect the market dynamics? What forces will shape the Nucleic Acid And Gene Therapies In Neuromuscular Disorders industry going forward?

The market major growth driver - Rising Prevalence Of Genetic Disorders Fuels Growth In The Market. For further insights on this market, request a sample here

What is the forecast market size or the forecast market value of the Nucleic Acid And Gene Therapies In Neuromuscular Disorders market?

The nucleic acid and gene therapies in neuromuscular disorders market size has grown strongly in recent years. It will grow from $6.84 billion in 2024 to $7.5 billion in 2025 at a compound annual growth rate (CAGR) of 9.6%. The growth in the historic period can be attributed to increase in regulatory approvals, demand for nucleic acid therapeutics, demand for more precise and effective therapies, demand for effective gene therapies, and increase in the number of gene therapy-based discoveries. The nucleic acid and gene therapies in neuromuscular disorders market size is expected to see strong growth in the next few years. It will grow to " $10.78 billion in 2029 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to increasing prevalence of genetic disorders, increasing investments in research and development, growing demand for precision medicine, rising approval of gene therapy products, and increasing prevalence of chronic disorders. Major trends in the forecast period include advances in patient care, high performance chromatography, innovative solutions for conditions, advancements in gene editing technologies, and availability of nucleic acid extraction technology. For further insights on this market, request a sample here

How is the Nucleic Acid And Gene Therapies In Neuromuscular Disorders market segmented?

The nucleic acid and gene therapies in neuromuscular disordersmarket covered in this report is segmented –
1) By Disorder: Motor Neuron Diseases; Neuropathies; Neuromuscular Junction Disorders; Myopathies Including Muscular Dystrophies
2) By Therapy: Adeno-Associated Viruses Gene Therapy; Postnatal Gene Therapy; Spinal Muscular Atrophy
3) By Application: Hospitals; Specialty Clinics; Ambulatory Surgery Centers Subsegments:
1) By Motor Neuron Diseases: Amyotrophic Lateral Sclerosis (ALS); Spinal Muscular Atrophy (SMA); Primary Lateral Sclerosis (PLS)
2) By Neuropathies: Charcot-Marie-Tooth Disease (CMT); Hereditary Sensory and Autonomic Neuropathy (HSAN); Peripheral Neuropathies
3) By Neuromuscular Junction Disorders: Myasthenia Gravis; Lambert-Eaton Myasthenic Syndrome (LEMS)
4) By Myopathies Including Muscular Dystrophies: Duchenne Muscular Dystrophy (DMD); Becker Muscular Dystrophy (BMD); Limb-Girdle Muscular Dystrophy (LGMD); Facioscapulohumeral Muscular Dystrophy (FSHD) For further insights on this market, request a sample here

Which region has the largest share of the Nucleic Acid And Gene Therapies In Neuromuscular Disorders market? What are the other regions covered in the report?

North America was the largest region in the nucleic acid and gene therapies in neuromuscular disorders market in 2024. The regions covered in the nucleic acid and gene therapies in neuromuscular disorders market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on this market, request a sample here.

Who are the major players in the Nucleic Acid And Gene Therapies In Neuromuscular Disorders market?

What are the key trends in the Nucleic Acid And Gene Therapies In Neuromuscular Disorders market?

Major trends in this market include Advancements In Gene Therapy For Neuromuscular Disorders. For further insights on this market, request a sample here.